Maurice Blake says he never knew that one-in-four black men face prostate cancer - double the average.

News, features, and commentary about cancer-related issues ...

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...

Researchers and clinicians from six leading medical centers and academic institutions—including the University of California San Diego—have collaborated to develop a new artificial intelligence model ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...